Treatment of renal anaemia with recombinant human erythropoietin results in decreased red cell uptake of 45Ca.
The ability of erythrocytes to undergo deformation may be of importance to erythrocyte survival and to blood flow resistance. In a previous study a decreased deformability was demonstrated in the erythrocytes of uraemic patients treated with recombinant human erythropoietin (rhEPO). Erythrocyte deformability is, at least partly, determined by the intracellular concentration of free calcium ions. Six patients with renal anaemia (initial haemoglobin 95 +/- 11 g/l) were treated with rhEPO. They were examined with regard to certain erythrocyte characteristics before treatment and after reaching a haemoglobin concentration exceeding 120 g/l. A decrease was noted upon treatment in erythrocyte deformability and uptake of 45Ca in vitro. The blood pressure tended to increase. The individual values of the decrease in 45Ca uptake and the increase in systolic blood pressure were positively correlated to each other (r = 0.87; p < 0.05). No correlation was found between changes in erythrocyte deformability and 45Ca uptake. The decrease in 45Ca uptake may be interpreted in two different ways. It could reflect a reduced membrane permeability to calcium ions, or, which is more probable, it could be the end result of an increase in the intracellular metabolic pool of free calcium ions caused by the rhEPO treatment. We, therefore, conclude that rhEPO treatment has certain effects on calcium homeostasis in erythrocytes which may be related to blood pressure regulation.
Linde
T
T
Department of Internal Medicine, University Hospital, Uppsala, Sweden.
Ronquist
G
G
Sandhagen
B
B
Wikström
B
B
Frithz
G
G
Pettersson
L
L
Danielson
B G
BG
D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D001809:Blood Viscosity / Q000187:drug effects; D002118:Calcium / Q000097:blood* / Q000493:pharmacokinetics; D002132:Calcium Radioisotopes; D004907:Erythrocyte Deformability / Q000187:drug effects; D004911:Erythrocyte Volume; D004912:Erythrocytes / Q000187:drug effects* / Q000378:metabolism*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D012044:Regression Analysis
D002132:Calcium Radioisotopes; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D002118:Calcium